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ABSTRACT: Silica nanostructures are widely investigated for theranostic
applications since relatively mild and easy synthetic methods allow the
fabrication of multicompartment nanoparticles (NPs) and fine modulation of
their properties. Here, we report the optimization of a synthetic strategy
leading to brightly fluorescent silica NPs with a high loading ability, up to 45
molecules per NP, of Sorafenib, a small molecule acting as an antiangiogenic
drug. We demonstrate that these NPs can efficiently release the drug and
they are able to inhibit endothelial cell proliferation and migration and
network formation. Their lyophilization can endow them with long shelf
stability, whereas, once in solution, they show a much slower release
compared to analogous micellar systems. Interestingly, Sorafenib released
from Pluronic silica NPs completely prevented endothelial cell responses and
postreceptor mitogen-activated protein kinase signaling ignited by vascular
endothelial growth factor, one of the major players of tumor angiogenesis. Our results indicate that these theranostic systems
represent a promising structure for anticancer applications since NPs alone have no cytotoxic effect on cultured endothelial
cells, a cell type to which drugs and exogenous material are always in contact once delivered.
■ INTRODUCTION
Vascular endothelial cells (ECs) are the first-line barrier for
injected drugs or medical devices as nanoparticles (NPs). It is
thus mandatory to ascertain the safety and lack of toxicity of
synthetic materials even before the study of their therapeutic
efficacy.
In the research discussed in this paper, we have concentrated
our attention on Sorafenib, a small molecule acting as an
antiangiogenic drug, able to inhibit the kinase moiety of the
vascular endothelial growth factor receptor (VEGFR)-2 and
other kinases.1 Vascular endothelial growth factor (VEGF)
plays an important role in tumor development, invasion, and
metastasis by promoting tumor angiogenesis.2,3 Several
malignancies are treated through the use of VEGFR tyrosine
kinase inhibitors (TKIs).4 In particular, Sorafenib is an orally
active multi-TKI that targets VEGFR-2 and -3, platelet-derived
growth factor receptor β, and Raf kinase, all of which have
been implicated in neovascularization and tumor progres-
sion.5,6 The Food and Drug Administration has approved the
use of Sorafenib for patients with renal cell carcinoma and
hepatocellular carcinoma, and the list of indications for this
drug is growing.7−12 Although remarkably well tolerated by
patients, Sorafenib exhibits a distinct pattern of adverse events
(AEs) that are thought to be related to the inhibition of
angiogenesis. Potentially, life-threatening AEs associated with
Sorafenib treatment include hypertension, hemorrhage, and
arterial and venous thromboembolism.13−17 Hemorrhagic
events have major negative impacts on mortality, morbidity,
and healthcare costs, often leading to treatment delays and
interruptions.17,18
An interesting general approach to limit anticancer drug AEs
is to design new formulations for their specific targeting and
slow drug release. In the last decades, several reports
demonstrated that nanotechnology can provide a promising
platform in medicine for carrying and delivering chemo-
therapeutic drugs by reducing side effects, increasing drug
accumulation at the tumor site, and improving blood
circulation.
Nanoparticles have been extensively applied in cancer
diagnosis and treatment exploiting their potentialities in single
or multidrug delivery.19 Therapeutic NPs can be designed to
accumulate at the tumor tissue/organ, where the active agent is
released, increasing the therapeutic efficacy by reducing the
dose, the incidence of the treatment, and the pernicious effect
on healthy sites. Moreover, once administered, NPs have the
intrinsic and general tendency to accumulate in the tumor
tissue/organ compared with healthy tissues.20 This tendency is
based on the enhanced permeability and retention (EPR)
effect. EPR is a consequence of the fact that solid tumors are
characterized by leaky blood vessels and hypoxia, which lead to
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the extravasation of NPs.21 This effect prolongs the retention
of nanomaterials within the pathological organ.
In addition to the EPR effect, nanomaterials can be also
engineered with functional groups on their surface (for
example, folic acid and hyaluronic acid) to obtain a more
specific target toward the tumor organs.22
One of the most interesting and promising chemical
matrixes used to develop theranostic nanostructures is silica
since its synthetic methods allow the fabrication of complex
nanoarchitectures where size and surface properties can be
modulated to control possible interactions with biomolecules,
a promising efficient cell internalization, and specific tissue
accumulation.23 Their versatile synthesis can allow obtaining
structures with different sizes (5 nm to 1 μm), porosities, and
shapes (such as disk, rod, spherical particles, hollow
sphere).24,25 Several different morphologies of silica nano-
particles are under investigation in clinical and preclinical tests,
aimed at the evaluation of the cytotoxicity and the
biocompatibility by oral or subcutaneous administration.26
Furthermore, the possibility to obtain nanostructures that can
be broken by suitable stimuli (pH, reducing agents, light)
inside cells and tissues can allow silica NPs to properly modify
drug delivery and excretion processes, increasing their efficacy
and reducing even more their long-term risks.27,28
In this context, we recently developed the synthesis of
multicompartment silica core/poly(ethylene glycol) (PEG)
shell nanoparticles, named Pluronic silica (PluS) NPs, obtained
with a one pot direct micelles template approach, developing
many bright luminescent materials29,30 for applications in in
vitro31 and in vivo32,33 optical and photoacoustic34 imaging as
chemosensors35 or as electrochemiluminescent probes.36
Interestingly, all of the experiments performed so far in vitro
on several cell lines and in vivo showed the absence of toxicity
in the useful concentration range.31
To optimize the advantages and efficacy for the application
of these PluS NPs in vivo, we are interested to develop suitable
strategies for the obtainment of theranostic materials, with
photothermal therapy,34 drug delivery, and optical imaging
capabilities. In this context, we present here the design of a
modified synthetic approach of these luminescent NPs
conceived to entrap a large number of Sorafenib molecules
while keeping release kinetics that could be compatible with an
in vivo use.
In addition, we present also a modification of the overall
formulation adopted to maintain the property of nanoparticles,
including drug content and colloidal stability, stable over time
with a long shelf time. To obtain this goal, freeze-drying, also
known as lyophilization, is one of the most used techniques.
Freeze-drying is a process that consists of removing water from
a frozen sample by sublimation and desorption under vacuum.
Nevertheless, this process generates various stresses during
freezing and drying steps; for this reason, species protectants,
such as monosaccharides, oligosaccharides, proteins, or other
polymers [PEG, poly(vinylpyrrolidone) (PVP)], are usually
added to the formulation to protect the nanoparticles from
freezing and desiccation stresses.37 In particular, freeze-drying
has been considered as a good technique to improve the long-
term stability of colloidal nanoparticles, especially aimed at
drug delivery purposes since dehydration can avoid drug leaks
from the nanocarriers. The main goal for a freeze-drying
process applied to theranostic nanoparticles is to obtain well-
dispersible nanocarriers, stable over time and moreover after
rehydration. This is a key factor for the application of freeze-
dried nanoarchitectures in a biological environment since
colloidal properties of the carrier affect the behaviors during
the application.38,39 The strategy that we propose here is based
on the use of PVP as a protectant to yield one of the smallest
PEG/silica nanoarchitectures as a potential nanocarrier for
Sorafenib with a simple preparation, high fluorescence
brightness, and long-term colloidal stability.40
The aim of the study was twofold: (i) to evaluate PluS NPs
safety on endothelial cells in basal conditions (1% serum) and
after stimulation (5% serum) and (ii) to characterize the effect
of Sorafenib released by these NPs on endothelial cell
morphology, viability, migration, and VEGF-induced angio-
genesis-related functions.
■ RESULTS AND DISCUSSION
Design of the Synthesis of Dye-Doped PluS NPs
Loaded with Sorafenib. A possible strategy for the
entrapment of lipophilic compounds by PluS NPs46,47 is
based on the presence, in these multicompartment structures,
of a lipophilic task close to the surface of the silica core.48 In
this way, we were able to obtain efficient chemosensors,
electrochemiluminescence labels,36 and photoswitching nano-
structures.49 As a first step, we tried to follow this strategy for
the inclusion of Sorafenib, but this approach was unsatisfactory
since the loading resulted to be relatively low (<10 drug
molecules per NP). Another embedding strategy is based on
the insertion of the active species in the nanoparticle core
during the synthesis. The first synthetic step for the
obtainment of PluS NPs is the formation of Pluronic F-127
micelles; the inclusion of Sorafenib into the micelle dispersion
led, in few minutes, to the complete dissolution of the drug,
otherwise insoluble in water. In the standard synthetic
procedure, this is followed by a second step in which the
silica precursor used for the formation of the PluS NPs,
tetraethylorthosilicate (TEOS),31 undergoes condensation in
the acidic aqueous media.43 This synthetic strategy led again to
a quite low Sorafenib entrapment in the NPs, which we
attributed to a not sufficiently fast (hours) hydrolysis kinetic of
the ethoxysilane derivative in these conditions. This finding
prompted us to substitute TEOS with tetramethoxyorthosili-
cate (TMOS), which is more reactive toward hydrolysis and
condensation and can react completely in a shorter timeframe.
To obtain fluorescent NPs, we inserted at this stage a
trimethoxysilane derivative of rhodamine B (RB) to covalently
attach the dye to the silica matrix (Figure 1). Also, in this case,
the choice of the derivative was adopted because of its faster
kinetics; the use of the analogous triethoxysilane derivative
lead to a 5-fold smaller doping degree (data not shown). It is
important to underline that the use of rhodamine was made
here to optimize the performances of the NPs for in vitro
Figure 1. Schematic representation of the synthesis of Sorafenib
tosylate (SRF)-loaded Pluronic F-127 silica nanoparticles function-
alized with rhodamine.
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studies since microscopes are seldom equipped for near-
infrared (NIR) light excitation and detection. However, the
versatility of the synthesis of PluS NPs opens up the possibility
to use a wide range of dyes including NIR ones, as cyanines,
that could allow for in vivo fluorescence imaging, photo-
acoustic imaging, and photothermal therapy.29−34
The importance to limit the release of Sorafenib during
synthesis suggested also to change the purification system,
moving from dialysis (∼1 day) to a much faster size exclusion
chromatography (SEC) separation (Sephadex G-25), using
phosphate-buffered saline (PBS) as the mobile phase. From
transmission electron microscopy images [see the Supporting
Information (SI)], it is possible to observe that the diameter of
the silica core is 10 ± 1 nm, whereas the hydrodynamic
diameter obtained with dynamic light scattering (DLS)
measurements (see SI) was 30 nm. This value is slightly
larger than the usual hydrodynamic diameter measured for
PluS NPs (25 nm), probably because of the use of TMOS
instead of TEOS. The possible limitation related to the storage
of PluS NPs stock dispersion, in which Sorafenib can leach
from the NPs, has been addressed, optimizing a lyophilization
protocol (reported in the Experimental Section) to obtain PluS
NPs in the form of a “ready to use” water-dispersible solid
powder. The choice of PVP K30 as the protecting agent was
motivated by the fact that it is a water soluble, cheap, and
nontoxic polymer for the efficient passivation of surfaces. In
addition, PVP was preliminarily tested to assess its potential
cytotoxic effect. Human umbilical vein endothelial cells
(HUVECs) were exposed to PVP concentrations ranging
from 1 to 100 nM, in excess with respect to the final
formulation. Our experiments did not evidence any toxic effect
on cell viability (see SI, p S7). This step provided a
formulation of SRF-PluS NPs with long-term shelf stability
that is not affected by any drug release after preparation. The
final averaged dye doping degree consists of six rhodamine B
moieties, conferring to the NPs a quite high brightness
(εNPs,565nm = 6 × 10
5 M−1 cm−1; ΦF = 0.21, Table 1), making
them suitable for optical imaging. As far as the drug loading
was concerned, each NP was able to host 45 Sorafenib
molecules (Table 1), a very significant amount considering the
small total volume of the nanostructure. After this preparation,
1 mg of lyophilized solid corresponds to 25 μg of Sorafenib.
This formulation was used for all of the following experiments.
Sorafenib Release and Nanoparticle Stability. The
absorption spectrum of Sorafenib inside the nanoparticles
presents a very similar profile to the one shown by the drug in
methanol solution, with an absorption maximum at 265 nm. As
already mentioned, the water solubility of Sorafenib is very
poor and precipitation occurs at very low concentration (>10−5
M). This means that the quantity of Sorafenib that is
vehiculated in water by the NPs is higher than its solubility
and the drug, when released, precipitates, producing a decrease
in its absorbance and an increase in scattering. Therefore, it
was possible to investigate its release from the NPs measuring
the decrease of absorbance at 265 nm (Figure 2). This method
allows the release kinetics to be directly monitored, and it can
be more accurate than other assays, such as dialysis or
chromatography, where the separation process can alter the
kinetics themselves.10,11
The amount of released Sorafenib from PluS NPs to the
bulk solution was obtained by the equation
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The drug molecules entrapped in the PluS NPs diffuse
spontaneously and almost quantitatively during 6 h, a much
longer time if compared with the few minutes measured for the
Pluronic F-127 micelle architecture, at the same Sorafenib
concentration (0.5 μM, Figure 2).
To verify the stability of the nanoparticles, we monitored
their hydrodynamic diameter during the drug release by DLS
analysis (Figure 3). The DLS distributions confirm, as
expected, that the hydrodynamic diameter remains constant
at about 33 nm over all of the observed period (3 days).
The data presented so far demonstrated that these NPs have
suitable stability and drug release capability to allow their
potential use as a drug carrier. Therefore, we proceeded with
biological tests to investigate the in vitro effects of this
nanocarrier preparation on cells present in the tumor
microenvironment.
Morphology of HUVEC Following Treatment with
NPs. First, we evaluated the cell morphology and cytoskeletal
organization of endothelial cells treated or not with PluS NPs.
The concentration of NPs was chosen to have a concentration
of Sorafenib equal to the one used, as a control, for the free
drug. The localization and intensity of the cytoskeletal proteins
β-actin and vimentin were evaluated by immunofluorescence.
In the presence of NPs, cell morphology was unaltered with
respect to the control conditions (1% serum), demonstrating
that NPs alone had no cytotoxic effect (Figure 4A).
Immunofluorescence analysis revealed that both in control
conditions (1% serum) and in the presence of NPs alone, β-
actin labeling was spread in the cytoplasm and stress fibers
could be seen in both conditions (Figure 4B). Accordingly,
vimentin intermediate filaments were visible in both conditions
(Figure 4C).
Table 1. Amount of Reagents and Main Morphological and Photophysical Properties of Lyophilized Nanoparticles
name F-127 (mg)
SRF
(mg)
TMOS
(μL)
PBS
(μL) RB-TMS (mg)
no of
RB/NPa
no of
SRF/NPa dH (nm) + SD PDI
λmax,abs
(nm)
λmax,em
(nm) ΦFb
NPs 200 250 3200 0.8 6 30 ± 5 0.352 562 591 0.20
SRF-NPs 200 19 250 3200 0.8 6 45 32 ± 6 0.430 563 590 0.21
aMeasured by absorption spectra. bMeasured using rhodamine B in ethanol (Φref = 0.96) as the reference.
Figure 2. Left: absorbance spectra variation of SRF-PluS NPs (2.5 ×
10−7 M) during the drug release. Right: trend comparison of the drug
release of SRF-F127 micelles vs PluS NPs. PBS pH 7.4, 37 °C.
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Effect of NPs Loaded with Sorafenib on HUVEC
Proliferation, Migration, and Cord Formation. Cell
survival (evaluated as cell number) in medium with 1 and
5% fetal bovine serum (FBS) was monitored at 24 and 48 h. In
control conditions, 1 and 5% serum, HUVEC cells increased in
number with time. The growth was higher with 5% FBS.
Incubation of the cells with NPs alone or with SRF-PluS NPs
had no effect on the cell number, strengthening their nontoxic
effect. On the contrary, free Sorafenib (used at the same
concentration of the one loaded on NPs) significantly reduced
cell growth. The reduction was higher with 1% serum and after
48 h incubation (Figure 5).
Inhibition of cell proliferation induced by free Sorafenib was
accompanied by an impairment of cell migration evaluated by
the scratch assay (Figure 6). In control conditions (1 and 5%
serum added to the medium) and in the presence of NPs, the
wounds completely healed. On the contrary, free Sorafenib
inhibited cell migration. When Sorafenib was loaded on NPs,
the impairment of cell migration was lower (Figure 6).
Finally, cord formation on Matrigel was evaluated as a
morphometric assay of in vitro angiogenesis. While in the basal
condition of untreated cells HUVEC was organized in cords
and networks with interconnected circles, in all of the other
conditions (free Sorafenib, NPs alone, and SRF-PluS NPs), the
formation of circles was completely blunted (Figure 7).
Figure 3. Left: hydrodynamic size distribution of the nanocarriers before and after the drug release (red, SRF-F127; blue, SRF-NPS). Right:
schematic representation of the two different mechanisms of the drug reservoir conducted by Pluronic F-127 silica nanoparticles vs Pluronic F-127
micelles.
Figure 4. Morphology of HUVEC following treatment with NPs. (A) After 24 h of cell exposure to NPs (diluted to obtain the similar final
concentration of NPs as Sorafenib 5 μM loaded NPs, used in the following experiments) in medium containing 1% serum, cells were fixed, stained,
and photographed using the microscope (10×). (B, C) Immunofluorescence for cytoskeletal proteins. Cells, stimulated for 24 h with NPs (diluted
to obtain the similar final concentration of NPs as Sorafenib 5 μM loaded NPs) in medium containing 1% serum, were fixed and immunostained for
(B) β-actin and (C) vimentin. Pictures were taken using the fluorescence microscope (63×).
Figure 5. Cell number evaluated in HUVEC treated with Sorafenib (5 μM) and NPs and SRF-PluS NPs (diluted to obtain the similar final
concentration of Sorafenib) for 24 and 48 h. The experiments were performed in medium containing 1 and 5% of serum. Data were expressed as
cells counted/well ± standard error (SE). * p < 0.05, ** p < 0.01, and *** p < 0.001 vs control conditions.
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From these series of data obtained on freshly prepared and
loaded NPs, nontoxic per se, we can hypothesize that the
Sorafenib inhibitory effect on endothelial cells (both quiescent
and stimulated with serum) is reduced when the drug is loaded
on silica NPs, from which it is released partially and slowly
during time, with respect to the free drug, which massively
blunts the responses of endothelial cells.
Effect of NPs Loaded with Sorafenib on VEGF-
Induced Angiogenic Activity in HUVEC. Next, the
antiangiogenic effects of Sorafenib-loaded NPs were assayed
in different in vitro assays and in the molecular readout of
VEGF-induced receptor activation, namely, phosphorylation of
ERK1/2. First, the antiproliferative effect of Sorafenib was
tested on endothelial cells exposed to VEGF (25 ng/mL) in
medium with 0.1% serum. In these conditions, after 24 h,
VEGF doubled the number of cells. This effect was inhibited
by free Sorafenib, NPs, and SRF-PluS NPs, in a similar
manner. NPs alone tended to have some inhibitory activity per
se (Figure 8A).
The effect of SRF-PluS NPs was tested on HUVEC
migration induced by VEGF (25 ng/mL) in medium
containing 0.1% FBS. Similar to proliferation, the inhibitory
effect on VEGF-induced HUVEC migration was obtained with
Sorafenib released by silica NPs, with NPs alone being
inhibitory but less effective (Figure 8B). The inhibitory effect
of NPs alone could be due to the experimental condition used
to reveal the proangiogenic effect of VEGF, i.e., a very low
serum condition.
Next, the potential inhibitory effect of Sorafenib on the
molecular readout of VEGF-induced activation in endothelial
cells was assessed by means of ERK1/2 phosphorylation
(Figure 9). Indeed, VEGFR-2 activation by VEGF in target
cells leads to mitogen-activated protein kinase (MAPK)
cascade with the final ERK1/2 phosphorylation. Cells were
pretreated for 6 h with the test substances and then stimulated
with VEGF (25 ng/mL) for 10 min. VEGF alone and in the
presence of NPs induced a strong ERK1/2 activation, whereas
the pretreatment with Sorafenib alone or released by silica NPs
completely prevented MAPK signaling ignited by VEGF. The
effect of 1 and 5 μM Sorafenib released by NPs was similar,
documenting that these two concentrations were maximal.
Overlapping results were obtained by pretreating the cells with
NPs for 1 h, suggesting that 1 h is enough to release active
Sorafenib.
■ CONCLUSIONS
In conclusion, we present here a new interesting platform for
theranostics that we have designed and prepared, taking
advantage of the versatility of the silica synthetic strategies, i.e.,
fluorescent silica core/PEG shell nanoparticles, named PluS
NPs, with a high loading ability of Sorafenib moieties, up to 45
molecules per NP, and with a much slower release compared
to the analogous micellar system. An added value is their long
shelf stability that has been obtained by an efficient
lyophilization of the Sorafenib-loaded NPs (SRF-PluS NPs).
Interestingly, we demonstrated that SRF-PluS NPs are able to
inhibit cell proliferation, migration, and network formation and
Figure 6. Cell migration was evaluated using the scratch assay on
HUVEC treated with Sorafenib (5 μM) and NPs and SRF-PluS NPs
(diluted to obtain the similar final concentration of Sorafenib). The
experiments were performed in medium containing 1 and 5% of
serum. Representative pictures of wounded cell monolayers are shown
on the right. The bar graph represents the quantification of cell
migration expressed as the percentage of the wound area.
Figure 7. Morphogenic assay on Matrigel was performed on HUVEC
treated with Sorafenib (5 μM) and NPs and SRF-PluS NPs (diluted
to obtain the similar final concentration of Sorafenib) in medium
containing 5% FBS. Representative pictures of network organization
are shown on the right. The bar graph represents the quantification of
the number of circles monitored after 18 h.
Figure 8. Effect of Sorafenib-loaded NPs on VEGF-induced EC
proliferation and migration. (A) Cell number evaluated in HUVEC
treated with Sorafenib (5 μM) and NPs and SRF-PluS NPs (diluted
to obtain the similar final concentration of Sorafenib), with or without
VEGF (25 ng/mL), for 24 h. The experiment was performed in
medium containing 0.1% FBS. Data were expressed as cells counted/
well ± SE. (B) Cell migration was evaluated using the scratch assay on
HUVEC pretreated (6 h) with NPs and SRF-PluS NPs (diluted to
obtain the similar final concentration of Sorafenib 5 μM), with or
without VEGF (25 ng/mL); the experiment was performed in
medium containing 0.1% FBS. Representative pictures of wounded
cell monolayers are shown.
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that the drug, once released, completely prevents endothelial
cell responses and postreceptor MAPK signaling ignited by
VEGF, one of the major players of tumor angiogenesis. Our in
vitro data document that this innovative preparation is safe, but
only animal studies will definitely document both its safety and
efficacy in models of pathology, parameters strongly necessary
before any use in the clinic. The versatility of the synthesis of
PluS NPs can also allow their doping with NIR emitting dyes,
as cyanines, possibly yielding nanostructures able to combine
optical imaging, photoacoustic imaging, drug delivery, and
photothermal therapy, further increasing their theranostic
potential.
■ EXPERIMENTAL SECTION
The UV−vis spectra were recorded with a PerkinElmer
Lambda 45 spectrophotometer. The fluorescence spectra
were recorded with a PerkinElmer LS55 spectrofluorimeter.
All of the samples were placed in a quartz cuvette with 1 cm
optical path length. Hydrodynamic diameters and size
distributions of PluS NPs, Sorafenib-loaded PluS NPs (SRF-
PluS NPs), and SRF-F127 micelles were determined using
dynamic light scattering (DLS). DLS measurements were
carried out using a Malvern Zetasizer Nanoseries equipped
with a 633 nm laser. All DLS measurements were performed in
PBS (pH 7.4) at 25 °C and at a scattering angle of 173°. For
each sample, mean hydrodynamic sizes and polydispersity
index (PDI) were determined from three measurements of the
autocorrelation function using cumulant analysis. Reported
mean hydrodynamic diameters for each condition were
determined by averaging values from triplicate measurements.
Errors on mean hydrodynamic diameters were calculated from
the standard deviation (SD) of values obtained from triplicate
measurements.
Materials. Reagents and solvents were used as received
without further purification: dimethyl sulfoxide (DMSO, 98%,
reagent grade, Sigma), methanol (98%, reagent grade, Sigma),
water (Milli-Q, 18.2 μS), tetramethyl orthosilicate (TMOS,
98%, Sigma), Sorafenib tosylate (SRF, 99%, Santa Cruz
Biotech), Pluronic F-127 [avg. molecular weight (MW) = 12
600 g/mol, Bioreagent, Sigma, F-127], 3-isocyanatopropyl-
trimethoxysilane (95%, Gelest), poly(vinylpyrrolidone) K30
(avg. MW = 40 000 g/mol, Sigma, PVP), triethylamine (TEA,
reagent grade, Sigma), Sephadex G-25 (Sigma), and
phosphate-buffered saline (PBS, tablet, Sigma).
Rhodamine B Trimethoxysilane Derivative Synthesis.
Rhodamine B piperazine derivative (10 mg, 1.9 × 10−5 mol, 1
equiv)41 was dissolved in a 1.5 mL plastic tube containing 0.5
mL of DMSO. Then, 3.3 × 10−6 L 3-isocyanatopropyltrime-
thoxysilane (1.9 × 10−5 mol, 1 equiv) and 6 × 10−6 L TEA
(3.8 × 10−5 mol, 2 equiv) were added. The reaction mixture
was stirred for 30 min and then used directly for the
nanoparticle preparation without any further purification.
Synthesis of PluS NPs Loaded with Sorafenib (SRF-
PluS NPs). The synthesis of Sorafenib tosylate-loaded silica
nanoparticles (SRF-PluS NPs) was carried out adapting
previously reported strategies.42,43 The process started with
the dissolution in a 20 mL scintillation vial containing 2 mL of
methanol, 19 mg of Sorafenib tosylate (2.98 × 10−5 mol SRF-
NPs, 0 mg for control NPs), and 200 mg of Pluronic F-127.
The organic solvent was removed under vacuum, and a well-
dried solid was recovered. This solid was dissolved in 3.2 mL
of PBS (pH 7.4). After the complete dissolution of the
surfactant and of the drug, 50 μL of a 38 mM DMSO solution
of rhodamine B trimethoxysilane derivative was added [RB-
Si(OMe)3]. Then, 250 μL of TMOS (1.68 × 10
−3 mol) was
added and the reaction mixture was stirred at room
temperature for 45 min. A volume of 0.5 mL of NPs
suspension was purified by size exclusion chromatography
(SEC) using Sephadex G-25 (8 mL), obtaining a final volume
of 1.5 mL.
NPs Freeze-Drying. To 1.5 mL of the purified nano-
particle solution, 100 μL of PVP K30 (10 wt %) was added as a
stabilizing agent for the freeze-drying step. The solution, then,
was immediately frozen with liquid nitrogen and then freeze-
dried for 24 h at −50 °C under vacuum (about 10−3 atm)
using a LABCO freeze dryer. At the end of the dehydration
procedure, a fine pink powder was recovered and stored at
about −18 °C. The nanoparticles resuspended even after a
period of 6 months after the freeze-drying maintained their
colloidal and drug release properties. The amount of SRF
contained in 1 mg of lyophilized solid corresponds to 25 μg
(drug loading has been observed to be constant up to 6
months after the preparation). The final averaged dye and drug
doping degree consist of six rhodamine B and 45 SRF
molecules per nanoparticle, respectively.
Estimation of the Nanoparticle Dye/Drug content.
The average number of dyes per particle was computed as
previously reported,30,42 considering the molar extinction
coefficient of the nanoparticles at λ = 565 nm (rhodamine B
signal) before and after the lyophilization and dividing this
value by the molar extinction coefficient of rhodamine B
(εEtOH, 565 nm = 1 × 10
5 M−1 cm−1). The concentration of NPs
obtained with this synthetic procedure has been evaluated with
different experimental techniques as previously reported.42 The
signal of the rhodamine B in the nanoparticle dispersion was
used as an internal reference to compute the average number
Figure 9. Effect of Sorafenib-loaded NPs on VEGF signaling in
HUVEC. (A) Western blot analysis of ERK1/2 phosphorylation in
HUVEC protein lysates. Cells were pretreated with Sorafenib (1 and
5 μM) and NPs and SRF-PluS NPs (diluted to obtain the similar final
concentration of Sorafenib) for 6 h, with or without VEGF (25 ng/
mL, 10 min). (B) Ratio of arbitrary densitometric units (A.D.U.) of
phospho-ERK1/2 to total ERK1/2.
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of Sorafenib molecules physically entrapped inside the NP,
considering the molar extinction coefficient of the drug in
methanol (εMeOH, 267 nm = 3.9 × 10
4 M−1 cm−1).
Drug Release Kinetics. UV−vis analysis was used to
evaluate the release of Sorafenib from the nanoparticles. The
UV−vis spectrum of the drug shows a narrow band centered at
265 nm only when perfectly solubilized (as in the case of
organic solvent solutions, see Figures S5 and S6, SI). When
SRF is dispersed in water (even at 1 × 10−6 M), the 265 nm
absorption band becomes less intense with respect to that
shown in an organic solvent. This spectral behavior can be due
to the aggregation of Sorafenib in aqueous solutions since this
drug is insoluble in water (Figure S5). Experimentally, the
kinetics were recorded with a Varian Cary 50 Bio
spectrophotometer. A small amount of lyophilized SRF-PluS
NPs or of SRF and F-127 (SRF-F127) was dispersed to the
same final concentration of Sorafenib (1.1 × 10−5 M) and of
the carrier (2.5 × 10−7 M) with PBS (pH 7.4) in a 1 cm optical
path quartz cuvette. The carrier was the NP or a comparable
amount of Pluronic F-127 surfactant. During the acquisition of
the kinetic experiments, the solution was stirred at 1000 rpm at
37 °C. A UV−vis absorption spectrum each for 10 min for
SRF-F127 and 45 min for SRF-NPs was recorded in the
wavelength range 240−750 nm (scan speed 480 nm/min).
Cell Cultures. Human umbilical vein endothelial cells
(HUVECs) were purchased from Promocell (Heidelberg,
Germany) and were grown in endothelial growth medium-2,
containing VEGF, R3-IGF-1, hEGF, hFGF, hydrocortisone,
ascorbic acid, heparin, and GA-1000 (Lonza, Basel, Switzer-
land); 10% fetal bovine serum (FBS) (Hyclone, EuroClone,
Milan, Italy); and 2 mM glutamine, 100 units/mL penicillin,
and 0.1 mg/mL streptomycin (Merck KGaA, Darmstadt,
Germany). Cells were cultured at 37 °C in 5% CO2 and used
until passage 10.
We have tried to characterize the nanoparticle hydro-
dynamic size in serum, but, in this medium, the scattering of
proteins is so strong that it hides the nanoparticle scattering
signal. At the same time, the presence of large concentrations
of proteins and of their aggregates makes the DLS technique
unsuitable to perform a reliable characterization since the level
of polydispersity of the suspension is too high. However, in
previous works,32,33 we investigated the colloidal behavior of
Pluronic silica nanoparticles in PBS in the presence of
increasing concentration of bovine serum albumin (BSA)
(up to 6 mg/mL). In these conditions, we observed that the
Pluronic silica nanoparticles maintain their colloidal stability
and monodispersity, experimenting a 2−4-fold increase in their
hydrodynamic diameter (BSA concentration range 0−5.6% w/
v), depending on the surface architecture of the Pluronic silica
nanoparticle.
Experimental Design. The experiments were designed to
evaluate the effect of Sorafenib-loaded PluS NPs having
Sorafenib concentrations at 1 and 5 μM. The experimental
controls were represented by no treatment (control condition,
Ctrl), NPs alone (at the same concentration as the ones loaded
with the drug, NPs), and free drug (Sorafenib, 1 or 5 μM).
Two types of NP preparations were used: the first one freshly
prepared before cell treatment and the second one with
lyophilized NPs, reconstituted in medium before cell
challenging.
Immunofluorescence Analysis. The cytoskeletal and
intermediate filament proteins β-actin and vimentin were
monitored by fluorescence analysis. A total of 5 × 104
HUVECs were seeded on 1 cm circular glass coverslips placed
into 24-well Multiwell plates and then exposed to NPs (at the
concentration corresponding to 5 μM Sorafenib) in medium
containing 1% FBS. After 24 h incubation, cells were fixed in
acetone for 5 min. After blocking of unspecific bindings with
3% bovine serum albumin (BSA), cells were incubated
overnight at 4°C with the primary antibodies [anti β-actin
(1:70, Sigma) and anti-vimentin (1:50, Cell Signaling, Milan,
Italy)] in 0.5% BSA in PBS. Samples were then incubated with
a secondary antibody tetramethylrhodamine conjugated
(Sigma) in PBS with 0.5% BSA for 90 min. Coverslips were
mounted in fluoromount (Sigma-Aldrich), and pictures of
stained cells were taken by fluorescence microscopy at 63×
magnification.44
Cell Number and Morphology. Cells were seeded at a
density of 2.5 × 104 on immunofluorescence coverslips located
in 24-well Multiwell plates. After 24 h, NPs with and without
Sorafenib (1 and 5 μM) were added to culture medium
containing 1 or 5% serum. Where indicated, cells were
stimulated with VEGF (25 ng/mL) in medium with 0.1% FBS.
After 24, 48, or 72 h of incubation, cells were fixed with 100%
methanol and stained with hematoxylin and eosin to monitor
the cell morphology and number. Living and attached cells
were counted randomly in 10 fields/sample at 20× original
magnification as previously reported.45
Scratch Assay. HUVECs (1 × 105 cells) were seeded on
the bottom of 12-well Multiwell plates precoated with gelatin.
Once HUVEC reached the confluence, cells were scratched
using a sterile 100−1000 μL micropipette tip to create a
wound ±500 μm across the monolayer. Each well was washed
with PBS to remove detached cells. Cells were exposed to NPs
with and without Sorafenib (5 μM) in medium with 1 and 5%
FBS. Where indicated, cells were stimulated with VEGF (25
ng/mL) in medium with 0.1% FBS after a 6 h preincubation
with NPs with and without Sorafenib (5 μM). The antimitotic
ARA-C (2.5 μg/mL) was added in all of the transwells to
evaluate only migration. Images of the wound in each well
were acquired from 0 to 18 h using a phase contrast
microscope (Nikon Eclipse TE 300, Nikon, Tokyo, Japan) at
20× magnification. The rate of migration was measured by
quantifying the uncovered area of the wound that HUVEC
covered starting from the edge of the scratch. Results are
expressed as the percentage of the wound area.45
Tube Formation Assay. Endothelial cells were plated on
solidified Matrigel (1.5 × 105 cells in a 12-well Multiwell
plate). After 18 h of incubation with NPs with and without
Sorafenib (5 μM) in medium with 5% FBS, endothelial cells
were photographed and network formation on Matrigel was
measured by means of the number of circles (Nikon Eclipse
E400 and Nikon DS-5MC camera).45
Western Blotting for ERK1/2 Phosphorylation. Phos-
phorylation of ERK1/2 was evaluated by western blotting as
previously described.44,45 Sparse and serum-starved HUVECs
seeded in 60 mm Petri dishes were pretreated for 1 or 6 h with
NPs with or without Sorafenib (1 and 5 μM) before the
stimulation with 25 ng/mL VEGF for 10 min. Cytosolic
fractions were obtained by the use of lysis buffer with the
following composition: 50 mM Tris−HCl, 1% Triton-X, 1 mM
Na3VO4, 1 mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid, 0.2 mM phenylmethanesulfonyl
fluoride, 25 μg/mL leupeptin, 10 μg/mL aprotinin, 10 mM
NaF, and 150 mM NaCl. After centrifugation at 16 000 g for
20 min at 4 °C, the supernatant was collected and proteins
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were assayed. Electrophoresis was carried out in 4−12% Bis−
Tris gels (Life Technologies, Carlsbad, CA). Proteins were
then blotted onto activated nitrocellulose membranes,
incubated overnight with the antibody anti phospho-ERK1/2
(Cell Signalling Technology, Euroclone, Pero, Milan, Italy)
diluted 1:1000 in PBS containing 1% dried milk and 0.05%
Tween 20, and then detected by an enhanced chemilumi-
nescence system (GE Healthcare, Milan, Italy). Results were
normalized to those obtained using an antibody against total
ERK1/2 (Cell Signalling Technology, Euroclone, Pero, Milan,
Italy).
Immunoblots were analyzed by densitometry using NIH
ImageJ 1.48v software, and the results, expressed as arbitrary
density units (A.D.U.) ± SD, were normalized to β-actin.
Data Analysis and Statistical Procedures. Results are
either representative or the average of at least three
independent experiments done in triplicate. Statistical analysis
was performed using analysis of the variance test followed by
the Bonferroni test and the Student t test (when appropriate),
using GraphPad Prism version 4.00 for Windows (GraphPad
Software, La Jolla, CA). p < 0.05 was considered statistically
significant.
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